Monoclonal Antibody to Heart-type Fatty Acid Binding Protein (H-FABP)
| Code | Size | Price |
|---|
| MAB243Hu21-20ul | 20ul | £89.00 |
Quantity:
| MAB243Hu21-100ul | 100ul | £166.00 |
Quantity:
| MAB243Hu21-200ul | 200ul | £224.00 |
Quantity:
| MAB243Hu21-1ml | 1ml | £515.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
MDGI; FABP11; H-FABP; O-FABP; Hfabp; FABP3; Fatty Acid Binding Protein 3, Muscle And Heart; Mammary Derived Growth Inhibitor; Fatty Acid Binding Protein 11; Muscle fatty acid-binding protein; Heart-ty
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Heart-type Fatty Acid Binding Protein
Potency (Clone Number):
C10
Reactivity:
Ra;Po;
Source:
Monoclonal antibody preparation
Usage:
Western blotting: 0.5-5ug/mL
Immunohistochemistry: 5-50ug/mL
Immunocytochemistry: 5-50ug/mL
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-50ug/mL
Immunocytochemistry: 5-50ug/mL
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Fatty Acid Binding Protein 3, Muscle And Heart (FABP3) | RPB243Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||